tbuckley/cabot-search huggingface dataset:
AB1424-HPR Correlates of sleep in rheumatoid arthritis: a systematic review
Authors: S Gaffney, N. Kennedy, S. Hanley
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Over 50% of those with a diagnosis of Rheumatoid Arthritis (RA) experience poor sleep quality.<sup>Scott 2010</sup> This may result in altered health-related quality of life in addition to decreased daytime function. <h3>Objectives</h3> The aim of this systematic review is to identify and compile an account of the correlates of poor sleep in those with RA. <h3>Methods</h3> Two reviewers carried out literature searches of nine electronic databases. Literature was chosen based on the application of eligibility criteria, implementation of quality assessment and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Moher <i>et al</i> 2009 <h3>Results</h3> Fifteen full-text studies were included in the review – fourteen of cross-sectional design, and one randomised controlled trial (RCT). This included 3283 participants with a diagnosis of RA in accordance with the American College of Rheumatology criteria. The outcome measures included in the literature were largely heterogeneous in nature and therefore a meta-analysis was deemed to be unsuitable. <h3>Conclusions</h3> There is evidence within the literature to suggest that interactions between pain, fatigue, depression and functional ability play a role in sleep quality in those with RA. However, longitudinal data is required in order to determine the directionality of these relationships. The most prominent correlate of poor sleep is pain, with twelve studies identifying a positive association between the two variables. Conflicting evidence exsistswith regard to the association between sleep quality and disease activity, RA medications and patient demographics. <h3>References</h3> [1] Moher, D., Liberati, A., Tetzlaff, J. and Altman, D.G. (2009) 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement', PLoS Medicine, 6(7), 1–6, available: http://dx.doi.org/10.1371/journal.pmed.1000097. [2] Scott, D.L., Wolfe, F. and Huizinga, T.W. (2010) 'Rheumatoid arthritis', Lancet, 376(9746), 1094–108, available: http://dx.doi.org/10.1016/s0140-6736(10)60826-4 <h3>Disclosure of Interest</h3> None declared
Asymptomatic Hypothyroidism and Hypercholesterolemia
Authors: M J Ball, D Griffiths, M Thorogood
Journal: Journal of the Royal Society of Medicine (1991)

Hypothyroidism is a cause of secondary hyperlipidaemia. This study investigates the frequency of biochemically diagnosed hypothyroidism and its relationship with plasma cholesterol concentration in apparently healthy people. Thyroid function tests (total T4, TSH, and free T4) were performed on 272 apparently healthy men and women (179 vegetarians, 93 meat eaters) with a plasma cholesterol concentration above 7 mmol/l and on 90 individuals with a plasma cholesterol below 4.1 mmol/l who were matched for age, sex and dietary habits. Six per cent of those with a plasma cholesterol above 7 mmol/l had biochemical evidence of hypothyroidism as defined by a TSH greater than 10 mIU/l (reference range 1-6) and a low free T4 below 10 pmol/l (reference range 10.1-25). Eighty per cent of these people had a high titre of thyroid anti-microsomal antibodies. Of the 90 individuals with a plasma cholesterol level below 4.1 and the 25 randomly selected participants none had biochemical evidence of hypothyroidism. Hypothyroidism is relatively common in apparently healthy people with a raised plasma cholesterol. It appears no commoner in vegetarians than in meat eaters.
Layer-Specific Physiological Features and Interlaminar Interactions in the Primary Visual Cortex of the Mouse
Authors: Yuta Senzai, Antonio Fernandez-Ruiz, György Buzsáki
Journal: Neuron (2019)

The relationship between mesoscopic local field potentials (LFPs) and single-neuron firing in the multi-layered neocortex is poorly understood. Simultaneous recordings from all layers in the primary visual cortex (V1) of the behaving mouse revealed functionally defined layers in V1. The depth of maximum spike power and sink-source distributions of LFPs provided consistent laminar landmarks across animals. Coherence of gamma oscillations (30-100 Hz) and spike-LFP coupling identified six physiological layers and further sublayers. Firing rates, burstiness, and other electrophysiological features of neurons displayed unique layer and brain state dependence. Spike transmission strength from layer 2/3 cells to layer 5 pyramidal cells and interneurons was stronger during waking compared with non-REM sleep but stronger during non-REM sleep among deep-layer excitatory neurons. A subset of deep-layer neurons was active exclusively in the DOWN state of non-REM sleep. These results bridge mesoscopic LFPs and single-neuron interactions with laminar structure in V1.
AB0210 Clinical and musculoskeletal ultrasound assessment of therapeutic response to tofacitinib in patients with rheumatoid arthritis: real-world clinical experience from a single centre in hong kong
Authors: C.K.-L. Yu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Increasingly, musculoskeletal ultrasound (MSUS) has been demonstrated as an effective method for monitoring disease activity and joint damage in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> The objective of this single-centre, 12 week study was to evaluate the effects of tofacitinib therapy in Chinese patients with RA using clinical, laboratory and sonographic assessments, with the view to identifying factors that may predict response to tofacitinib. Furthermore, the study sought to determine whether MSUS would be comparable to conventional techniques for monitoring disease activity in RA. <h3>Methods</h3> Patients with RA (n=18) were treated with tofacitinib 5 mg bd for 12 weeks. Clinical, laboratory and ultrasound examinations were conducted at baseline (T0), and weeks 4 (T1), 8 (T2) and 12 (T3). Erythrocyte sedimentation rate, C-reactive protein, physician and patient visual analogue scale for disease activity, number of tender and swollen joints, Clinical Disease Activity Index (CDAI), Simple Disease Activity Index (SDAI) and Disease Activity Score in 28 joints (DAS28) were assessed and compared. MSUS was performed bilaterally in all metacarpophalangeal, interphalangeal, wrist and knee joints. A semi-quantitative score (0–3) was used to indicate the presence of a localised inflammatory process and/or structural damage. The cumulative total was used as an indicator of global change in each joint (single joint score). The sum of the single joint scores was used as an indicator of overall polyarticular involvement in each patient (total joint score). <h3>Results</h3> Of the 18 patients recruited into the study, all 18 were examined at T0, T1 and T2, and 17 patients were evaluated at T3. All clinical and laboratory measures, as well as MSUS scores, were significantly reduced during follow-up. There was a significant correlation between MSUS scores and conventional (clinical and laboratory) measures of disease activity. Correlation coefficients between the techniques and factors potentially predicting response to tofactinib will be reported. <h3>Conclusions</h3> A positive response to tofacitinib treatment was shown by both MSUS examination and clinical evaluation, with good correlation between the methods. In a busy, every-day, clinical-practice setting in Hong Kong, MSUS was found to be a useful tool for monitoring and following-up the effects of biologic therapy in RA, for the assessment of both inflammatory and destructive changes. <h3>Disclosure of Interest</h3> None declared
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial
Authors: Alan P Skarbnik, Michele L. Donato, Robert Korngold, Rena Feinman, Scott D. Rowley, Andre Goy, David H. Vesole, Pashna N. Munshi, David S Siegel, Tatyana A. Feldman, Noa Biran, Lori A. Leslie, Michael B Atkins, Andrew L. Pecora
Journal: Blood (2018)
Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML
Authors: Joshua F Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Matthew C Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik W. Van Deventer, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, Katherine Pepin, Lori Vaught, Nancy Vogler, Kelsey Miller, Laurie Betts, Karen McKinnon, Dante S. Bortone, Joel S. Parker, Leo Luznik, Ivana Gojo, Jonathan S Serody
Journal: Blood (2018)
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
Authors: Veronika Vikova, Michel Jourdan, Nicolas Robert, Guilhem Requirand, Stéphanie Boireau, Angélique Bruyer, Laure Vincent, Guillaume Cartron, Bernard Klein, Olivier Elemento, Alboukadel Kassambara, Jérôme Moreaux
Journal: Theranostics (2019)

de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
AB0431 Earlier age at therapy initiation is associated with better response to tocilizumab therapy in patients with juvenile idiopathic polyarthritis
Authors: E. Alexeeva, T. Dvoryakovskaya, M. Soloshenko, R. Denisova, K. Isaeva, A. Mamutova, V. Gladkikh, A. Moskalev
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The use of therapy with anti-cytokine biologicals in routine practice has significantly increased the percentage of children showing good response to therapy and reduced the time to achieve pharmacological remission. Nevertheless, the problem related to selecting the optimal drug for a certain patient still remains to be solved. <h3>Objectives</h3> This study was aimed at identifying clinical and laboratory parameters associated with response to tocilizumab (TOC) treatment in patients with RF-negative polyarticular JIA. <h3>Methods</h3> The prospective study to assess TOC efficacy involved 55 patients with RF-negative polyarticular JIA aged 9.42 years (IQR 5.96–13.42), with females (85.5%) predominating was conducted at the National Medical Research Centre of Children's Health (Moscow). Treatment efficacy was evaluated using the ACRPedi criteria; Wallace's criteria were used to assess whether a patient had reached inactive disease or remission. The potential baseline characteristics associated with treatment response were identified using univariate and multivariate logistic regression analyses. Baseline factors included the clinical, laboratory, and anamnestic data. <h3>Results</h3> TOC therapy showed high efficacy in children with RF-negative polyarticular JIA: 81.8/67.3/47.3/23.6% of patients reached the ACR30/50/70/90 criteria for the end of follow-up, respectively. The median time of achieving at least 30% improvement from baseline (ACR30) was 1 months (IQR 1:3). Univariate analysis showed that earlier age at initiation of Tocilizumab therapy, higher physician's global assessment score using the 100-point Visual Analogue Scale, and longer morning stiffness were the factors associated with reaching ACR90. Younger age at therapy initiation, greater number of swollen joints and joints with limited range of motion, and history of using fewer biologicals are the factors associated with reaching inactive disease and remission. However, multifactorial analysis showed that only earlier age at initiation of TOC therapy was a statistically significant factor associated with reaching the best response to therapy in all the models. <h3>Conclusions</h3> Earlier initiation of TOC therapy is associated with higher chances for reaching ACR90 and pharmacological remission in patients with RF-negative polyarticular JIA. Further studies in larger cohorts are needed to identify the optimal age at therapy initiation. <h3>Disclosure of Interest</h3> E. Alexeeva: None declared, T. Dvoryakovskaya Grant/research support from: Roche, Pfizer, M. Soloshenko: None declared, R. Denisova: None declared, K. Isaeva: None declared, A. Mamutova: None declared, V. Gladkikh: None declared, A. Moskalev: None declared
THU0023 Complex immunophenotyping stratifies patients with primary sjÖgren’s syndrome, systemic lupus erythematosus and secondary sjÖgren’s syndrome associated with systemic lupus erythematosus into distinct clinically relevant groups with potential therapeutic implications
Authors: N. Thompson, A. Gandhi, R. Radmmore, V. Gupta, G. Robinson, L. Martin-Gutierrez, D. Isenberg, E. Jury, C. Ciurtin
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Similarities in the clinical and laboratory features of patients with primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE) have led to attempts to treat pSS and SLE patients with similar biologic therapeutics. However, the results of many clinical trials are disappointing and no effective treatments are available for pSS and few for SLE patients with refractory disease. <h3>Objectives</h3> To identify novel patient endotypes using in depth immune phenotyping that facilitates the selection of biological therapies for patients regardless of diagnostic labels. <h3>Methods</h3> Peripheral blood was collected from patients with pSS (n=55), SLE (n=38), SS/SLE (n=15) and age/sex-matched healthy controls (HCs) (n=34). In-depth phenotyping of peripheral B and T-cell subsets by flow-cytometry, followed by unsupervised cluster analysis were performed. ROC analysis identified immune signatures characteristic for every cluster (endotype). <h3>Results</h3> Patients with pSS, SLE and SS/SLE had both unique and shared defects in immune cell phenotype. Hierarchical clustering of CD19<sup>+</sup> B-cells, CD4<sup>+</sup> and CD8<sup>+</sup> T-cells across the three disease groups identified five distinct endotypes spanning diagnostic boundaries. Three of the endotypes had distinct immune signatures, characterised by predominantly B-cell, T-cell memory or CD4<sup>+</sup>/CD8<sup>+</sup> T-cell subset fingerprints respectively, while two clusters had no distinct immune profiles. Notably, clinical and disease features were not significantly different between clusters. <h3>Conclusions</h3> The results demonstrated that immune cell biomarkers could be used to re-classify patients in a manner that reflects their underlying immunopathogenesis. Characterisation of a patient's endotype could lead to better stratification of patients for selection of therapeutic targets in clinical trials. <h3>References</h3> [1] Nocturne, G. &amp; Mariette, X. Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol2013;9:544–556. [2] Sada, P.R., Isenberg, D. &amp; Ciurtin, C. Biologic treatment in Sjogren's syndrome. Rheumatology (Oxford)2015;54:219–230. <h3>Disclosure of Interest</h3> None declared
SP0052 Posttranslational modification of autoantibodies in ra
Authors: L. Trouw
Journal: Annals of the Rheumatic Diseases (2018)

Rheumatoid Arthritis (RA) is a common autoimmune disease in which autoantibodies serve as interesting biomarkers. In a large proportion of the patients several types of autoantibodies are present that target post-translationally modified proteins. Next to antibody responses against citrullinated proteins (ACPA) we now also describe antibody responses against carbamylated proteins (anti-CarP) in RA. The use of these autoantibodies in the prediction, diagnosis and prognosis will be discussed, as well as the clues, obtained in animal models, as to how such an antibody response may be initiated.  In addition the findings that antibodies themselves are also post-translationally modified and the functional consequences of such modifications will be highlighted both regarding carbamylation of IgG and modifications of ACPA IgG.  Disclosure of Interest  None declared
At the Line in the Sand, On the Bridge in the Rain, On the Borders That Do Not Exist
Authors: Carol Snyder Halberstadt
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Authors: Robert W. Chen, Lu Chen, Alex F. Herrera, Matthew Mei, Katrina McBride, Rosie Abary, Tanya Siddiqi, Leslie Popplewell, Stephen J Forman, Steven T Rosen, Larry W Kwak
Journal: Blood (2018)
Abstract 19504: Sudden Cardiac Death in Takotsubo Syndrome: Results From a Multicenter, International Registry
Authors: Sebastiano Gili, Susanne A Schlossbauer, Victoria L Cammann, Ken Kato, Beatrice Bacchi, Flurina Famos, Katharina Ding, Burkhardt Seifert, Fabrizio D'Ascenzo, Jelena R Ghadri, Christian Templin
Journal: Circulation (2017)

Introduction: Cardiac arrest (CA) has been often reported in Takotsubo syndrome (TTS), however scarce data is available on the true prevalence and the natural history of this event. Hypothesis: To ...
SAT0310 The associations of serum il18 and osteoprotegerin (OPG) levels with the lipid profile in psoriatic arthritis (PSA) patients
Authors: K. Bonek, P. Gluszko, E. Kontny
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> We have previously found that IL-18 and OPG serum concentrations are correlated with cardiovascular (CV) risk in psoriatic arthritis but not in ankylosing spondylitis (AS) patients.<sup>1</sup> <h3>Objectives</h3> To investigate whether in PsA patients the association of OPG and IL-18 with CV risk is mediated by an impact of these cytokines on lipid profile changes. <h3>Methods</h3> 49 patients with PsA (25 M/24 F) with (n=10) and without (n=39) coronary heart disease (CHD), and 25 sex and age matched (mean age 44,4 vs 43,4 years) patients with AS were enrolled. Disease activity was measured by DAPSA (25,17±19,9) in PsA group and by BASDAI (5,37±2) and ASDAS- CRP (3,18±1) in AS group. The lipid profile (triglycerides – TG, total cholesterol – tChol, low- and high-density lipoprotein – LDL and HDL, respectively), systemic inflammation markers and cytokines (OPG, IL-18) were measured in patients serum samples. Atherogenic index (AI=tChol/HDL) was calculated. Statistical analysis was performed using Mann-Whitney U-test and Spearman's Rank test. Data are expressed as mean values. <h3>Results</h3> Patients with PsA presented more atherogenic lipid profile than AS patients because of their higher TG levels (153 vs 126,6 mg/dl; p=0,05) and AI values (3,83 vs 3,24; p=0,05) while lower HDL concentrations (51,6 vs 61,4 mg/dl; p=0,04). Compared to AS group, PsA patients were characterised by higher IL-18 (235 vs 208 pg/ml; p&lt;0,05) but lower OPG (815 vs 1660 pg/ml; p&lt;0,05) serum levels. In PsA patients without CHD, serum OPG positively but moderately correlated with LDL (r=0,3; p=0,05), TG (r=0,43; p=0,007) and AI (r=0,45 p=0,004). Moreover, in this PsA patients subgroup we confirmed previously observed<sup>1</sup> inverse correlation of IL-18 with HDL levels (r=-0,34; p=0,05) and positive correlation of this cytokine with both TG levels (r=0,37; p=0,04) and AI values (r=0,53; p=0,002). Interestingly, similar but stronger associations of IL-18 with HDL levels (r=-0,88; p=0,004) and AI values (r=0,88; p=0,004) were presently found in PsA patients with accompanied CHD. Consistently with our previous report,<sup>1</sup> we failed to find any correlations between CV risk, lipid profile, and tested cytokines serum concentrations in patients with AS. <h3>Conclusions</h3> We report that in PsA, but not AS, patients serum IL-18 and OPG concentrations are correlated with an altered and pro-atherogenic lipid profile. These associations are stronger in patients with concomitant CHD. Thus, present results explain partially the way by which these cytokine contribute to CV complications in PsA. <h3>Reference</h3> [1] Kontny E, et al. Association of serum osteoprotegerin and IL-18 concentrations with cardiovascular risk in ankylosing spondylitis and psoriatic arthritis. Ann Rheum Dis2017;76(suppl 2):1310–1311AB0733. <h3>Disclosure of Interest</h3> None declared
Exome Sequencing of Extreme Phenotypes Suggests Novel Candidate Genes As Modifiers of Leg Ulcer in Sickle Cell Anemia
Authors: Gabriela Queila de Carvalho Siqueira, Galina Ananina, Murilo Guimarães Borges, Bruno Batista de Souza, Iscia Teresinha Lopes Cendes, Fernando F. Costa, Mônica Barbosa de Melo
Journal: Blood (2018)
The Role of Complement in Liver Injury, Regeneration, and Transplantation
Authors: Ebbe Billmann Thorgersen, Andreas Barratt‐Due, Håkon Haugaa, Morten Harboe, Søren Erik Pischke, Per H. Nilsson, Tom Eirik Mollnes
Journal: Hepatology (2019)

The liver is both an immunologically complex and a privileged organ. The innate immune system is a central player, in which the complement system emerges as a pivotal part of liver homeostasis, immune responses, and crosstalk with other effector systems in both innate and adaptive immunity. The liver produces the majority of the complement proteins and is the home of important immune cells such as Kupffer cells. Liver immune responses are delicately tuned between tolerance to many antigens flowing in from the alimentary tract, a tolerance that likely makes the liver less prone to rejection than other solid organ transplants, and reaction to local injury, systemic inflammation, and regeneration. Notably, complement is a double‐edged sword as activation is detrimental by inducing inflammatory tissue damage in, for example, ischemia–reperfusion injury and transplant rejection yet is beneficial for liver tissue regeneration. Therapeutic complement inhibition is rapidly developing for routine clinical treatment of several diseases. In the liver, targeted inhibition of damaged tissue may be a rational and promising approach to avoid further tissue destruction and simultaneously preserve beneficial effects of complement in areas of proliferation. Here, we argue that complement is a key system to manipulate in the liver in several clinical settings, including liver injury and regeneration after major surgery and preservation of the organ during transplantation.